Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Director resigns, liquidation fear looms as Phoslock struggles to raise funds after China problems

  • In News
  • September 5, 2023
  • Alinda Gupta
Director resigns, liquidation fear looms as Phoslock struggles to raise funds after China problems

In 2020, water treatment company Phoslock Environmental Technologies (ASX: PET) came under the scanner for accounting irregularities and fraud in its China division. Subsequently, the Company’s financials suffered and it also lost some staff in China. 

Three years later, PET’s China management team has been restructured to reduce costs and focus resources on revenue-generating activity. General Manager Viktor Li left the Company on August 31 after helping stabilise the operations in China following the previous mismanagement issues. Will Li has been appointed to the senior regional commercial role and legal representative for PET’s China sales entity.

Closer to home, Phoslock’s non-executive Director Barry Sechos has thrown in the towel, with his resignation effective from September 6, 2023. Furthermore, the Company will relocate its Corporate Head Office as part of its overall cost reduction program. 

Phoslock informed that it will not be filling Sechos’s position on the Board.

PET has been struggling to gain funding to keep operations going. Its board meetings held on August 10 and August 29, 2023 reviewed various cash flow projections and the statement of financial position. The Board concluded that Phoslock’s ability to keep going as an operational and profitable business, i.e. a going concern, depends on its ability to raise significant additional funds. 

As Phoslock explores funding sources, it is not able to say with certainty whether its efforts will bear fruit. In the absence of adequate funding or alternative transactions in a timely manner, the directors plan to put a resolution to shareholders for voluntary winding-up of the Company. 

In keeping with that, the directors have determined that the going concern basis of accounting is no longer appropriate. Thus, the Company’s interim financial statements were prepared on a non-going concern, i.e. close to liquidation, basis. 

In H1 FY23, the Company reported a revenue of $1 million, down 20% on H1 FY22, and an NPAT loss of $5.2 million. Its net operating cash outflow was $3.5 million. Existing project delays, lack of new projects and fluctuating freight rates put a damper on PET’s objectives.  

On a positive note, in August, PET informed that it had secured a part payment of about $642k in respect of a receivable associated with the Xingyun Lake project in China. The payment was made to PET’s Beijing based subsidiary, Beijing Ecosystime Environmental Science and Technology Co. However, this payment represents just under 10% of the principal owed, which is $7.05 million, with efforts continuing to secure the balance.

Plus, it secured orders for Phoslock applications in Brazil and Finland, with a combined value of $600k, scheduled for September.

Even so, the Company is not very hopeful about its future. The new contract revenues and sales rebuild are not enough to support business operations, remaining well below expectations and requirements. The Company plans on sharing its full FY23 results by September 8, which will determine the way forward.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx pet
  • Barry Sechos
  • Phoslock
  • water treatment
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.